scispace - formally typeset
J

Jesús Reviriego

Researcher at University of Extremadura

Publications -  10
Citations -  133

Jesús Reviriego is an academic researcher from University of Extremadura. The author has contributed to research in topics: Nifedipine & Ketanserin. The author has an hindex of 7, co-authored 10 publications receiving 130 citations. Previous affiliations of Jesús Reviriego include Autonomous University of Madrid.

Papers
More filters
Journal ArticleDOI

Actions of vasoactive drugs on human placental vascular smooth muscle.

TL;DR: 5-HT is the most potent vasoconstrictor agent of all those tested, whose effects appear to be mediated by 5-HT2- but not by alpha 1-adrenergic receptors; (2) chorionic vessels also possess H1-receptors; and ketanserin has more affinity to block 5- HT2- receptors than to blockalpha 1- adrenergic- and H 1-receptionors.
Journal ArticleDOI

Action of adenosine and characterization of adenosine receptors in human placental vasculature.

TL;DR: It is concluded that there exists a similar population of adenosine A1 and A2 receptors in chorionic vessels, which mediateAdenosine relaxation, which appears to be mainly produced by inhibition of Ca influx, but not by a cAMP-dependent mechanism.
Journal ArticleDOI

The effects of BAY-K-8644 on the contraction of cat middle cerebral and femoral arteries.

TL;DR: The results suggest that BAY-K-8644 facilitates Ca2- influx into smooth muscle through Ca2+ channels that are possibly voltage sensitive and the voltage independence of the drug-induced contractions in cerebral arteries.
Journal ArticleDOI

Effects of 5-hydroxytryptamine on human isolated placental chorionic arteries and veins.

TL;DR: The results indicate that 5‐HT responses in these vessels were greatly dependent on extracellular Ca2+ and may desensitize the latter by interconversion between a high affinity and low affinity state, as suggested by others.
Journal ArticleDOI

Ability of ketanserin to block different receptors in human placental vessels.

TL;DR: 5‐HT is the most potent constrictor agent tested in human chorionic arteries and veins, and its effects are mediated by 5‐HT2‐receptors, and ketanserin at therapeutic plasma concentrations (10−7 M) seems to block mainly 5‐ HT2‐ receptors; and α1‐adrenergic‐ and H1‐receptionors to a small extent only.